Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2015 Genitourinary Cancers Symposium /
Combination of pazopanib and paclitaxel safe in urothelial cancer

26th - 28th Feb 2015

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 26.02.15
Views: 2195
Rating:

Prof Sandy Srinivas - Stanford University Medical Centre, Stanford, USA

Prof Srinivas talks to ecancertv at ASCO GU 2015 about the results of a phase II study which looked at the use of pazopanib with weekly paclitaxel in refractory urothelial cancer.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation